Real-revenue cases
Founder Zee, dealing with his own hair loss, formulated a topical anti-DHT hair product (Retain) from clinical literature, made early batches in his basement, beta-tested on friends and friends-of-friends, launched October 2017, self-reported $76K/month, and shut down in 2023.
01
Hair loss is a persistent anxiety-driven need, and the product positions itself against oral drugs with sexual side effects, so a side-effect-free topical does attract paying users. But topical efficacy is hard to verify, churn is likely when users see no change within months, and the business shut down in 2023 — demand existed, retention and scale did not.
Consumers buy Retain directly through a Shopify storefront, with MailChimp for email marketing. Unit price, repeat-purchase rate, and margins are not given.
Oral hair-loss drugs with sexual side effects, and existing treatments that mask symptoms rather than address the DHT cause.
02
A beta group of the founder's friends and friends-of-friends, briefed on the science, signed onto risk waivers, then given free product with monthly check-ins.
03
Not an AI business itself, but the path of 'founder's own pain point → beta with a small circle → then scale' transfers directly to AI apps: prove retention with yourself and a small group before spending on acquisition.
04
Revenue basis · Founder self-reported, unaudited (see source page)
The $76K/month figure is founder self-reported and unaudited; unit price, repeat rate, margin, and CAC are all missing.
Claims like '95% success rate,' 'under $10K per formula,' and 'under 12 months to market' are unverified and inconsistent with the beta results of '100% stop, 70% regrowth.'
The shutdown reason is only listed as 'Shut down' — no indication whether it was demand, retention, regulatory, or supply chain, so failure attribution is impossible.